Payment overview · 2025
General Payments
$408.46
20 reported records · 15 companies
Healthcare provider profile · identity verified
Benjamin Sherman, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BAY MINETTE, AL · NPI 1134549074
Verified facts
What the public records show
CMS Open Payments records show Benjamin Sherman, MD received $408.46 in general payments during 2025 across 20 reported records.
AstraZeneca Pharmaceuticals LP accounted for 14.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 220 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $57.41 | 14.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.20 | 12.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $41.40 | 10.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.09 | 6.6% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $26.49 | 6.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $24.16 | 5.9% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.49 | 5.8% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $21.79 | 5.3% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.31 | 5.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.99 | 5.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.84 | 5.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.19 | 4.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.37 | 4.7% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $18.86 | 4.6% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $15.87 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $408.46 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $49.20 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $49.20 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $41.40 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $32.72 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $27.09 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $26.49 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $24.69 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.16 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $23.49 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $21.79 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $21.31 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 123 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 220 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 188 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
66 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
29 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
123 | 30 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
181 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
220 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
95 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
188 | 40 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 858 | 223 |
| Amlodipine Besylate | Amlodipine Besylate | 708 | 197 |
| Pantoprazole Sodium | Pantoprazole Sodium | 672 | 187 |
| Furosemide | Furosemide | 608 | 164 |
| Levothyroxine Sodium | Levothyroxine Sodium | 577 | 131 |
| Gabapentin | Gabapentin | 478 | 104 |
| Hydrochlorothiazide | Hydrochlorothiazide | 445 | 128 |
| Potassium Chloride | Potassium Chloride | 430 | 104 |
| Trazodone Hcl | Trazodone Hcl | 380 | 91 |
| Eliquis | Apixaban | 377 | 57 |
| Tramadol Hcl | Tramadol Hcl | 363 | 74 |
| Losartan Potassium | Losartan Potassium | 359 | 92 |
| Omeprazole | Omeprazole | 341 | 98 |
| Famotidine | Famotidine | 335 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 318 | 88 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 306 | 79 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 295 | 70 |
| Metformin Hcl | Metformin Hcl | 294 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 289 | 77 |
| Duloxetine Hcl | Duloxetine Hcl | 274 | 60 |
| Carvedilol | Carvedilol | 273 | 78 |
| Lisinopril | Lisinopril | 269 | 70 |
| Pravastatin Sodium | Pravastatin Sodium | 266 | 64 |
| Meloxicam | Meloxicam | 237 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 232 | 57 |
| Mounjaro | Tirzepatide | 220 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 208 | 81 |
| Tizanidine Hcl | Tizanidine Hcl | 208 | 57 |
| Montelukast Sodium | Montelukast Sodium | 197 | 56 |
| Ozempic | Semaglutide | 188 | 40 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 182 | 52 |
| Jardiance | Empagliflozin | 181 | 34 |
| Allopurinol | Allopurinol | 177 | 49 |
| Donepezil Hcl | Donepezil Hcl | 177 | 38 |
| Metformin Hcl Er | Metformin Hcl | 177 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 176 | 44 |
| Diclofenac Sodium | Diclofenac Sodium | 174 | 50 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 170 | 48 |
| Pregabalin | Pregabalin | 169 | 36 |
| Sertraline Hcl | Sertraline Hcl | 167 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 164 | 47 |
| Spironolactone | Spironolactone | 162 | 51 |
| Mirtazapine | Mirtazapine | 150 | 26 |
| Glimepiride | Glimepiride | 148 | 45 |
| Buspirone Hcl | Buspirone Hcl | 145 | 41 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 137 | 39 |
| Prednisone | Prednisone | 135 | 83 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 133 | 43 |
| Ondansetron Odt | Ondansetron | 129 | 58 |
| Fluticasone Propionate | Fluticasone Propionate | 127 | 60 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 126 | 21 |
| Farxiga | Dapagliflozin Propanediol | 123 | 30 |
| Xarelto | Rivaroxaban | 120 | 22 |
| Lorazepam | Lorazepam | 114 | 22 |
| Clonazepam | Clonazepam | 112 | 20 |
| Simvastatin | Simvastatin | 111 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 110 | 26 |
| Baclofen | Baclofen | 104 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 100 | 26 |
| Estradiol | Estradiol | 99 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 96 | 17 |
| Trulicity | Dulaglutide | 95 | 19 |
| Celecoxib | Celecoxib | 93 | 31 |
| Finasteride | Finasteride | 91 | 16 |
| Alprazolam | Alprazolam | 90 | 13 |
| Clonidine Hcl | Clonidine Hcl | 87 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 87 | 21 |
| Fluconazole | Fluconazole | 86 | 50 |
| Aripiprazole | Aripiprazole | 85 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 82 | 59 |
| Cephalexin | Cephalexin | 78 | 54 |
| Glipizide Er | Glipizide | 78 | 23 |
| Levetiracetam | Levetiracetam | 78 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 18 |
| Propranolol Hcl | Propranolol Hcl | 74 | 19 |
| Ketoconazole | Ketoconazole | 73 | 44 |
| Mupirocin | Mupirocin | 73 | 40 |
| Bupropion Xl | Bupropion Hcl | 72 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 16 |
| Lamotrigine | Lamotrigine | 72 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 72 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 72 | 40 |
| Alendronate Sodium | Alendronate Sodium | 71 | 23 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 70 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 70 | suppressed |
| Azithromycin | Azithromycin | 69 | 58 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 69 | 18 |
| Valsartan | Valsartan | 69 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 68 | 22 |
| Linzess | Linaclotide | 66 | 13 |
| Memantine Hcl | Memantine Hcl | 64 | 17 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 63 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | 15 |
| Temazepam | Temazepam | 62 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 60 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 60 | 47 |
| Doxycycline Hyclate | Doxycycline Hyclate | 58 | 37 |
| Paroxetine Hcl | Paroxetine Hcl | 58 | 16 |
| Cefdinir | Cefdinir | 57 | 47 |
| Solifenacin Succinate | Solifenacin Succinate | 57 | 23 |
| Humalog | Insulin Lispro | 56 | suppressed |
| Januvia | Sitagliptin Phosphate | 56 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 16 |
| Azelastine Hcl | Azelastine Hcl | 55 | 31 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 55 | 15 |
| Primidone | Primidone | 54 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 54 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 53 | 18 |
| Verapamil Er | Verapamil Hcl | 53 | 15 |
| Methocarbamol | Methocarbamol | 52 | 14 |
| Sucralfate | Sucralfate | 52 | suppressed |
| Atenolol | Atenolol | 51 | 13 |
| Promethazine Hcl | Promethazine Hcl | 51 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 50 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 50 | 18 |
| Clonidine | Clonidine | 49 | 12 |
| Lactulose | Lactulose | 49 | 23 |
| Methylprednisolone | Methylprednisolone | 48 | 39 |
| Amiodarone Hcl | Amiodarone Hcl | 47 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 47 | 24 |
| Ezetimibe | Ezetimibe | 44 | 14 |
| Divalproex Sodium | Divalproex Sodium | 43 | suppressed |
| Lovastatin | Lovastatin | 43 | suppressed |
| Synthroid | Levothyroxine Sodium | 43 | 11 |
| Chlorthalidone | Chlorthalidone | 42 | 12 |
| Levofloxacin | Levofloxacin | 42 | 34 |
| Olanzapine | Olanzapine | 40 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 39 | 15 |
| Diltiazem Hcl | Diltiazem Hcl | 39 | suppressed |
| Topiramate | Topiramate | 39 | suppressed |
| Colchicine | Colchicine | 36 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 15 |
| Latanoprost | Latanoprost | 36 | suppressed |
| Nitroglycerin | Nitroglycerin | 36 | 19 |
| Propranolol Hcl Er | Propranolol Hcl | 36 | 12 |
| Valacyclovir | Valacyclovir Hcl | 36 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 28 |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 34 | suppressed |
| Tradjenta | Linagliptin | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 33 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | 11 |
| Naproxen | Naproxen | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 31 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 30 | 11 |
| Carbamazepine | Carbamazepine | 29 | suppressed |
| Prolia | Denosumab | 29 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 28 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Eszopiclone | Eszopiclone | 27 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 27 | suppressed |
| Ibuprofen | Ibuprofen | 26 | 16 |
| Methenamine Hippurate | Methenamine Hippurate | 26 | suppressed |
| Movantik | Naloxegol Oxalate | 26 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 24 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 24 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Haloperidol | Haloperidol | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 17 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 20 |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | suppressed |
| Ibu | Ibuprofen | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Nystatin | Nystatin | 18 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 17 | suppressed |
| Belsomra | Suvorexant | 16 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 16 | 16 |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | 13 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 12 |
| Minoxidil | Minoxidil | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Scopolamine | Scopolamine | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Cholestyramine Light | Cholestyramine | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | 12 |
| Cilostazol | Cilostazol | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $408.46 · 20 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, EVENITY, FARXIGA, GVOKE HYPOPEN, IBSRELA, Kerendia, LOREEV XR, MOUNJARO, Ohtuvayre, Omnipod, Ozempic, QULIPTA, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, WATCHMAN Access System, XIFAXAN | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error